Notice of initial substantial holder
Melbourne, Australia, 20 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 12 May 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
CLINUVEL progresses vitiligo study
CLINUVEL today announced that it will start treatment of vitiligo patients with...
Read More
Notification regarding unquoted securities
Melbourne, Australia, 6 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Appendix 4C & Activity Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...
Read More
Notice of ceasing to be a substantial holder
Melbourne, Australia, 27 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Initial Director’s Interest Notice
Melbourne, Australia, 7 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
CLINUVEL appoints new Non-Executive Director
Melbourne, Australia, 04 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Change of Director's Interest Notice
Melbourne, Australia, 23 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Change of Director's Interest Notice
Melbourne, Australia, 02 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
CLINUVEL Reports Record December Half Year Operating Profit
Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Appendix 4D - ASX Listing Rule 4.2A.3 Half Yearly Report
Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read More
Change of Director’s Interest Notice
Melbourne, Australia, 19 January 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
Notification of Cessation of Securities
Melbourne, Australia, 19 January 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read More
CLINUVEL Expands Pharmaceutical Portfolio
Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders
Read More